Our FAK Inhibitors
Amplia's initial clinical development pipeline currently comprises two novel orally available small molecule FAK inhibitors:
- AMP945 – Highly selective (FAK-only)
- AMP886 – Highly differentiated, multi-action (FAK/FLT3/VEGFR3)
Preclinically, both AMP945 and AMP886 have demonstrated excellent potency and selectivity, together with very promising pharmacokinetics and physical-chemistry properties.
Drug manufacturing scale-up chemistry has already been developed in partnership with a leading international commercial contract manufacturer. The production methods developed are suitable for GMP production of clinical trial material and due to the common synthetic route for both molecules, large scale manufacturing should be highly cost effective.